We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 82.50
Bid: 80.00
Ask: 85.00
Change: 0.00 (0.00%)
Spread: 5.00 (6.25%)
Open: 82.50
High: 82.50
Low: 82.50
Prev. Close: 82.50
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MOU with Quest Teleradiology

11 Oct 2021 07:00

RNS Number : 5665O
Feedback PLC
11 October 2021
 

RNS REACH

 

Feedback plc

 

Feedback signs MOU with Quest Teleradiology to progress Bleepacommercial international opportunities

 

· Quest Teleradiology is an Indian based diagnostic and tele-reporting teleradiology service company with healthcare customers across India, the UK and Africa

· Bleepa enables image transfer from Quest customer sites to Quest Radiologists for reporting and presents the subsequent reports back to requesting clinicians

· Bleepa additionally enables two way dialogue between the referring clinician and reporting Radiologist, enhancing the clinical value of the teleradiology service 

 

London, 11 October 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical communication company, announces it has signed a Memorandum of Understanding with Quest Teleradiology Solutions ("Quest") to develop strategic opportunities for Bleepa, its flagship clinical communications platform, in the large and growing Indian healthcare market, the UK and internationally. Bleepa offers the opportunity to expand Quest's existing teleradiology service by enabling direct case discussion between requesting clinicians and reporting Radiologists alongside the traditional teleradiology reporting model.

 

Quest is one of India's emerging teleradiology organisations with customers across India, the UK and throughout Africa. Under the collaboration, Quest will be able to offer a more integrated reporting service to hospitals and trial Bleepa's technology with a number of its international customers to understand the added value that case discussion brings to traditional outsourced reporting models. In traditional outsourced reporting models, it is often difficult for a requesting clinician to discuss the case with the Radiologist who reports it, usually having to rely on email or switchboard coordinated calls in order to get answers to questions about the report. Similarly, it is difficult for the reporting Radiologist to get additional clinical information beyond what is contained in the imaging request, but which could enhance the quality of their report. This leads to customer dissatisfaction with many outsourced reporting services.

 

Quest is one of the first outsourced reporting services to assess the benefits of enhanced communication to their service offering. Both companies believe that case-based discussion will help the outsourced reporting service to feel like a fully embedded clinical service at customer sites, enhancing the value to the customer and helping to improve the quality of the reports generated by improving Radiologist access to clinical information at the time of reporting.

 

Combining Bleepa's mobile-based technology with Quest's teleradiology expertise, will create a blueprint for how outsourced services should be integrated into core clinical services using the Bleepa platform and will open growth opportunities for both companies in multiple markets.

 

Dr Karthik Gopal, CEO of Quest, commented: "Bleepa is an extremely exciting innovation that will mean that we will be able to offer Hospitals highly efficient access to our reporting resources as well as a service to our own customers which is quicker and more efficient than ever before."

 

Dr Tom Oakley, CEO of Feedback, added: "This collaboration is expected to put Bleepa in the hands of more clinicians and key stakeholders and we are delighted to have been chosen to enhance Quest's product offering. Quest brings significant expertise as well as a strong network of contacts, customers and opportunities through which we aim to introduce Bleepa. We look forward to working with Quest and opening up new markets across all international territories."

 

-Ends-

 

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

+44 (0)1954 718072

IR@fbk.com

 

 

Panmure Gordon (UK) Limited (NOMAD and Broker)

Emma Earl/Freddy Crossley (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Paul McManus/Nick Rome/Nicholas Johnson

07980 541 893 or 07748 325 236 or 07884 664 686

 

Notes to Editors

 

Feedback plc (AIM: FDBK) is a pioneer of regulated clinical communication products. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

 

Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care providers. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of clinical review.

 

About Quest Teleradiology - http://www.questteleradiology.com/ 

Quest Teleradiology Solutions is a Bangalore based company that provides complete radiology services extending from diagnostic business development to Tele reporting. Quest Teleradiology is a team of experienced Doctors, operational managers and IT experts committed to improving healthcare through technology, committed to make healthcare cost effective and to bridge the gap in service delivery through technology. Currently Quest services clients from Asia, Africa and Europe continents and is focussed to leverage technology to take healthcare to the needy at the right time and at affordable range, saving resources.

 

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUWUNRABURRAA
Date   Source Headline
30th Jun 201712:41 pmRNSIssue of Equity
8th Jun 20171:15 pmRNSCCI Exclusive Distributor Agreement with Korea ISG
8th Jun 20171:11 pmRNSDirectorate Change
1st Jun 20179:23 amRNSTotal Voting Rights
30th May 20174:38 pmRNSFurther re. Notice of Resignation of Director
18th May 20177:00 amRNSProgress with CE Mark and trading update
12th May 201711:57 amRNSHolding(s) in Company
2nd May 20177:00 amRNSNotice of Resignation of Director
26th Apr 20177:00 amRNSIssue of Equity
30th Mar 20177:00 amRNSLetter of Intent signed and trading update
3rd Mar 20177:00 amRNSAppointment of Joint Broker
20th Feb 20177:00 amRNSHalf-year Report
23rd Jan 20171:28 pmRNSRe: Media Articles
30th Nov 20165:00 pmRNSTotal Voting Rights
24th Nov 201612:44 pmRNSDirector/PDMR Shareholding
23rd Nov 20161:20 pmRNSIssue of Equity & Director / PDMR Shareholding
23rd Nov 201610:33 amRNSResult of AGM
16th Nov 20167:00 amRNSAttendance at RSNA 2016
19th Oct 20163:17 pmRNSRe: Directorate
19th Oct 20167:00 amRNSFinal results for the year ended 31 May 2016
21st Sep 201612:30 pmRNSTrading Update
28th Jul 20161:31 pmRNSCollaboration with Future Processing
1st Jun 201612:30 pmRNSAppointment of Non-Executive Chairman
3rd May 201612:00 pmRNSDisposal
2nd Mar 20167:00 amRNSChange of Nominated Adviser
22nd Feb 20167:00 amRNSInterim Results for the 6 months ended 30 Nov 2015
30th Nov 20152:59 pmRNSResult of AGM
23rd Nov 20157:00 amRNSTexRAD Update
6th Nov 20157:01 amRNSDirectorate Change
6th Nov 20157:00 amRNSFinal Results
8th Oct 20157:00 amRNSStrategy Update
6th Oct 20159:45 amRNSNHS publication on potential application of TexRAD
5th Oct 20157:00 amRNSTexRAD Prostate Cancer Product Development
28th Sep 20157:00 amRNSLicence of TexRAD to Stone Checker
9th Sep 20157:00 amRNSFirst sale of TexRAD in China
31st Jul 20157:00 amRNSTotal Voting Rights
20th Jul 20157:00 amRNSStudy Results
9th Jul 20158:39 amRNSExercise of Options
6th Jul 20152:08 pmRNSIssue of Equity
30th Jun 20157:00 amRNSTotal Voting Rights
12th Jun 20157:00 amRNSFirst server sale of TexRAD in Canada
4th Jun 20159:56 amRNSStmnt re Share Price Movement
3rd Jun 20157:00 amRNSIssue of Equity
15th May 20157:00 amRNSCollaboration with University of Texas
11th May 20153:09 pmRNSPreliminary results from the Oxford Stone Group
29th Apr 20157:00 amRNSDrug Trial and Trading Update
28th Apr 20157:00 amRNSCollaboration with Princess Alexandra Hospital, AU
27th Apr 20157:00 amRNSFirst sale of TexRAD in South Korea
23rd Apr 201512:15 pmRNSStmnt re Share Price Movement
20th Apr 20157:00 amRNSAdoption of TexRAD research software

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.